Stock Market Reviews

CSTL (Castle Biosciences, Inc.) News

Get the latest news, insights, and market updates on CSTL (Castle Biosciences, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
  FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expression for predicting outcomes in patients with uveal melanoma (UM). Th
  Dec 17, 2025 - $CSTL
• CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
  CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
  Dec 16, 2025 - $CSTL
• KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
  Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
  Dec 16, 2025 - $CSTL
• AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
  AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
  Dec 16, 2025 - $CSTL
• Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test
  Castle Biosciences (CSTL) just got a meaningful vote of confidence, as an independent panel of melanoma experts published a consensus paper endorsing its DecisionDx Melanoma test as part of best practice care. See our latest analysis for Castle Biosciences. The endorsement appears to be feeding into a powerful upswing, with Castle Biosciences’ share price delivering an 80.35% 3 month share price return and a 33.81% 1 year total shareholder return from a long term base that is still...
  Dec 13, 2025 - $CSTL
• Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
  Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified careFRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new systematic review and meta-analysis (SRMA) demonstrating that the TissueCypher® Barrett’s Esophagus test provid
  Dec 12, 2025 - $CSTL
• Are Medical Stocks Lagging Cronos Group (CRON) This Year?
  Here is how Cronos Group (CRON) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
  Dec 11, 2025 - $CSTL
• KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study
  Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
  Dec 9, 2025 - $CSTL
• Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
  Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanomaFRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cutaneous Melanoma: An Expert Consensus Panel,” which endorses the Company’s Deci
  Dec 9, 2025 - $CSTL
• Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date
  AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.
  Dec 9, 2025 - $CSTL